Biofrontera (NASDAQ:BFRI) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Biofrontera (NASDAQ:BFRI – Free Report) to a hold rating in a report published on Saturday.

Other research analysts also recently issued reports about the stock. Zacks Research downgraded shares of Biofrontera from a “hold” rating to a “strong sell” rating in a research report on Friday, July 3rd. Weiss Ratings upgraded shares of Biofrontera from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday. One equities research analyst has rated the stock with a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Reduce”.

Get Biofrontera alerts:

View Our Latest Stock Report on BFRI

Biofrontera Price Performance

Shares of BFRI stock opened at $1.09 on Friday. The firm has a market cap of $13.95 million, a P/E ratio of -1.12 and a beta of 0.81. Biofrontera has a fifty-two week low of $0.55 and a fifty-two week high of $1.21. The business’s 50 day moving average price is $0.97 and its 200-day moving average price is $0.93. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.09 and a current ratio of 1.20.

Biofrontera (NASDAQ:BFRI – Get Free Report) last posted its earnings results on Thursday, May 14th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.29). The business had revenue of $10.08 million for the quarter, compared to analysts’ expectations of $10.25 million. Biofrontera had a negative net margin of 25.66% and a negative return on equity of 515.34%. On average, equities research analysts anticipate that Biofrontera will post -0.3 earnings per share for the current year.

Hedge Funds Weigh In On Biofrontera

A hedge fund recently raised its position in Biofrontera stock. Rosalind Advisors Inc. increased its position in Biofrontera Inc. (NASDAQ:BFRI – Free Report) by 51.5% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 976,448 shares of the company’s stock after purchasing an additional 332,055 shares during the period. Biofrontera makes up approximately 0.3% of Rosalind Advisors Inc.’s holdings, making the stock its 27th biggest position. Rosalind Advisors Inc. owned 9.63% of Biofrontera worth $695,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 10.08% of the company’s stock.

About Biofrontera

(Get Free Report)

Biofrontera AG is a specialty biopharmaceutical company focused on the research, development and commercialization of products for dermatological applications. The company’s core expertise lies in photodynamic therapy (PDT), a treatment modality that uses a photosensitizing agent activated by a specific light source to target diseased skin cells while sparing surrounding healthy tissue.

The flagship product in Biofrontera’s portfolio is Ameluz (aminolevulinic acid hydrochloride 10 % gel), which has received marketing approval in the European Union for treatment of actinic keratosis and basal cell carcinoma, and in the United States for actinic keratosis.

Featured Articles

• Five stocks we like better than Biofrontera
• Netflix May Be Cheap Enough to Tempt Buyers After Earnings Drop
• Delta vs. United: Which Airline Is Better Built for Higher Fuel Costs?
• The Market Sold Alcoa After Earnings—But It May Be Missing the Real Story
• Why Intuitive Surgical’s Strong Quarter Still Spooked Investors

Receive News & Ratings for Biofrontera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biofrontera and related companies with MarketBeat.com's FREE daily email newsletter.